Neoadjuvant treatment for breast cancer
linical trials have shown that the status of the women achieving complete pathomorphological repression (CPR) of a tumor is characterized by significantly improved survival as compared to that of those who have not to an equal degree. The achievement of CPR as an intermediate marker for improved sur...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849403717954043904 |
|---|---|
| author | V. F. Semiglazov V. V. Semiglazov R. M. Paltuev G. A. Dashyan T. Yu. Semiglazova P. V. Krivorotko A. V. Komyakhov Zh. V. Bryantseva K. S. Nikolaev D. Ye. Shchedrin A. M. Yermochenkova |
| author_facet | V. F. Semiglazov V. V. Semiglazov R. M. Paltuev G. A. Dashyan T. Yu. Semiglazova P. V. Krivorotko A. V. Komyakhov Zh. V. Bryantseva K. S. Nikolaev D. Ye. Shchedrin A. M. Yermochenkova |
| author_sort | V. F. Semiglazov |
| collection | DOAJ |
| description | linical trials have shown that the status of the women achieving complete pathomorphological repression (CPR) of a tumor is characterized by significantly improved survival as compared to that of those who have not to an equal degree. The achievement of CPR as an intermediate marker for improved survival is chiefly observed in women with aggressive subtypes of breast cancer (BC): triple-negative and HER-2-positive. In patients with the latter subtype, addition of trastuzumab to neoadjuvant chemotherapy doubles the rate of CPR and correlates with higher survival rates. The performed clinical trials have established that neoadjuvant endocrine therapy is the most suitable treatment for patients with steroid hormone receptor overexpression. Whether it may be used in combination with targeted (anti-HER-2) therapy for estrogen and HER-2 coexpression is being investigated. Neoadjuvant therapy for suitable BC stages can accelerate the assessment of novel medications through identification of predictive biological markers for response (CPR in particular). Although standard neoadjuvant therapy gives an obvious benefit to patients with CPR, other patients with the so-called residual disease are at high recurrence risk. |
| format | Article |
| id | doaj-art-e0e4523ecc234f3bbd0abfd06791f427 |
| institution | Kabale University |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-e0e4523ecc234f3bbd0abfd06791f4272025-08-20T03:37:11ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272014-07-0102303610.17650/1994-4098-2014-0-2-30-3638Neoadjuvant treatment for breast cancerV. F. Semiglazov0V. V. Semiglazov1R. M. Paltuev2G. A. Dashyan3T. Yu. Semiglazova4P. V. Krivorotko5A. V. Komyakhov6Zh. V. Bryantseva7K. S. Nikolaev8D. Ye. Shchedrin9A. M. Yermochenkova10N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint PetersburgAcad. I.P. Pavlov Saint Petersburg State Medical University, Ministry of Health of RussiaRailway Clinical Hospital, Russian Railways, Saint PetersburgN.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint PetersburgN.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint PetersburgN.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint PetersburgAcad. I.P. Pavlov Saint Petersburg State Medical University, Ministry of Health of RussiaI.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint PetersburgN.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint PetersburgN.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint PetersburgN.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburglinical trials have shown that the status of the women achieving complete pathomorphological repression (CPR) of a tumor is characterized by significantly improved survival as compared to that of those who have not to an equal degree. The achievement of CPR as an intermediate marker for improved survival is chiefly observed in women with aggressive subtypes of breast cancer (BC): triple-negative and HER-2-positive. In patients with the latter subtype, addition of trastuzumab to neoadjuvant chemotherapy doubles the rate of CPR and correlates with higher survival rates. The performed clinical trials have established that neoadjuvant endocrine therapy is the most suitable treatment for patients with steroid hormone receptor overexpression. Whether it may be used in combination with targeted (anti-HER-2) therapy for estrogen and HER-2 coexpression is being investigated. Neoadjuvant therapy for suitable BC stages can accelerate the assessment of novel medications through identification of predictive biological markers for response (CPR in particular). Although standard neoadjuvant therapy gives an obvious benefit to patients with CPR, other patients with the so-called residual disease are at high recurrence risk.https://ojrs.abvpress.ru/ojrs/article/view/23breast cancerneoadjuvant therapy |
| spellingShingle | V. F. Semiglazov V. V. Semiglazov R. M. Paltuev G. A. Dashyan T. Yu. Semiglazova P. V. Krivorotko A. V. Komyakhov Zh. V. Bryantseva K. S. Nikolaev D. Ye. Shchedrin A. M. Yermochenkova Neoadjuvant treatment for breast cancer Опухоли женской репродуктивной системы breast cancer neoadjuvant therapy |
| title | Neoadjuvant treatment for breast cancer |
| title_full | Neoadjuvant treatment for breast cancer |
| title_fullStr | Neoadjuvant treatment for breast cancer |
| title_full_unstemmed | Neoadjuvant treatment for breast cancer |
| title_short | Neoadjuvant treatment for breast cancer |
| title_sort | neoadjuvant treatment for breast cancer |
| topic | breast cancer neoadjuvant therapy |
| url | https://ojrs.abvpress.ru/ojrs/article/view/23 |
| work_keys_str_mv | AT vfsemiglazov neoadjuvanttreatmentforbreastcancer AT vvsemiglazov neoadjuvanttreatmentforbreastcancer AT rmpaltuev neoadjuvanttreatmentforbreastcancer AT gadashyan neoadjuvanttreatmentforbreastcancer AT tyusemiglazova neoadjuvanttreatmentforbreastcancer AT pvkrivorotko neoadjuvanttreatmentforbreastcancer AT avkomyakhov neoadjuvanttreatmentforbreastcancer AT zhvbryantseva neoadjuvanttreatmentforbreastcancer AT ksnikolaev neoadjuvanttreatmentforbreastcancer AT dyeshchedrin neoadjuvanttreatmentforbreastcancer AT amyermochenkova neoadjuvanttreatmentforbreastcancer |